| Literature DB >> 12726855 |
Abstract
The prevailing view of cdk2 as a critical regulator of cell cycle progression and optimal therapeutic target in cancer cells is now challenged by the observation that tumor cells deficient in cdk2 protein and kinase activity are not impaired in proliferation.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12726855 DOI: 10.1016/s1535-6108(03)00084-9
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743